Hymenoptera venom allergy is a typical IgE-mediated mechanisms, with the exception of some aspects, which are anyway common to other allergic diseases. In fact, there is an high prevalence of hymenoptera venom specific IgE in the serum of subjects who experienced hymenoptera stings without presenting clinical symptoms; and more, there are patients presenting systemic symptoms after a sting who reach a natural tolerance at a subsequent sting. Hymenoptera venom studies about the risk factors related to venom sensitization allowed to prepare guidelines for the admission to venom specific immunotherapy (SIT), which is the only preventive treatment of fatal reactions. Anyway, despite its high efficacy, this treatment presents an high incidence of adverse reactions (4-6% in the literature). Up to now, several attempts have been done to improve venom SIT safety but no significant advantages have been reached. Follow-up studies on the duration of this treatment and the degree of protection induced by SIT showed a significant risk of resesitization after the discontinuation of the treatmet, which is higher in patients allergic to honey bee venom. So a revision of the actual criteria of venom SIT discontinuation is needed, based on clinical evaluation and not only on the actually used immunologic and chronologic criteria.
|Translated title of the contribution||Venon immunotherapy: State of the art|
|Number of pages||5|
|Publication status||Published - 2000|
ASJC Scopus subject areas
- Internal Medicine